# EDGAR Filing Document

**Accession Number:** 0001135951
**File Stem:** 0001575872-25-000488
**Filing Date:** 2025-7
**Character Count:** 8642
**Document Hash:** 1c17127dc0cd85bfd6d01dd9fa0169f6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001575872-25-000488.hdr.sgml**: 20250723

**ACCESSION NUMBER**: 0001575872-25-000488

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 5

**CONFORMED PERIOD OF REPORT**: 20250723

**FILED AS OF DATE**: 20250723

**DATE AS OF CHANGE**: 20250723

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** DR REDDYS LABORATORIES LTD
- **CENTRAL INDEX KEY:** 0001135951
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-15182
- **FILM NUMBER:** 251142750

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 8-2-337, ROAD NO.3 BANJARA HILLS
- **CITY:** HYDERABAD
- **PROVINCE COUNTRY:** K7
- **ZIP:** 500-034
- **BUSINESS PHONE:** 91 40 49002900

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 8-2-337, ROAD NO.3 BANJARA HILLS
- **CITY:** HYDERABAD
- **PROVINCE COUNTRY:** K7
- **ZIP:** 500-034

#### SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

Form 6-K

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16**

#### UNDER THE SECURITIES EXCHANGE ACT OF 1934
**July 2025**

**Commission File Number 1-15182**<br>

#### DR. REDDY'S LABORATORIES LIMITED
(Translation of registrant's name into English)

**8-2-337, Road No. 3, Banjara Hills**

**Hyderabad, Telangana 500 034, India**

#### +91-40-49002900
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ⌧ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F ◻

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______

**Note:** Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

**Note:** Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ◻ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No ⌧

If "Yes" is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.

**EXHIBITS** 

---

| | |
|:---|:---|
| **Exhibit <br>Number** | **Description of Exhibits** |
| [99.1](rdy0782_ex99-1.htm) | [Intimation dated July 23, 2025](rdy0782_ex99-1.htm) |

---

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | DR. REDDY'S LABORATORIES LIMITED <br>(Registrant) | DR. REDDY'S LABORATORIES LIMITED <br>(Registrant) |
| Date: July 23, 2025  | By: | /s/ K Randhir Singh |
|  |  | Name: K Randhir Singh |
|  |  | Title: Company Secretary  |

---

## Exhibit 99.1

**Exhibit 99.1**

---

| | |
|:---|:---|
| ![](rdy0782_ex99-1img01.jpg)<br>| **Dr. Reddy's Laboratories Ltd.**<br>8-2-337, Road No. 3, Banjara Hills<br>Hyderabad – 500 034, Telangana, India <br>CIN: L85195TG1984PLC004507<br>Tel:&nbsp;&nbsp;&nbsp;&nbsp; + 91 40 4900 2900<br>Fax:&nbsp;&nbsp;&nbsp;&nbsp; + 91 40 4900 2999<br>Email: <u>mail@drreddys.com</u><br>Web:&nbsp;&nbsp;&nbsp;&nbsp;<u>www.drreddys.com</u> |

---

July 23, 2025

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)

BSE Limited (Scrip Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

Dear Sir/Madam,

---

| | |
|:---|:---|
| **Ref:** | **<u>Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015</u>** |

---

Please find enclosed a Press Release *viz.* "Dr. Reddy's announces its intention to appoint M/s. Deloitte Haskins & Sells LLP as Statutory Auditors effective from FY 2026-27."

This is for your information and records.

Thanking you,

Yours faithfully,

For **Dr. Reddy's Laboratories Limited**

![](rdy0782_ex99-1img02.jpg)<br>

**K Randhir Singh**

*Company Secretary, Compliance Officer & Head-CSR*

Encl: as above.

![](rdy0782_ex99-1img03.jpg)<br>

**Dr. Reddy's announces its intention to appoint M/s. Deloitte Haskins &**

**Sells LLP as Statutory Auditors effective from FY 2026-27**

**Hyderabad India; July 23, 2025** - Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; "Dr. Reddy's or the Company"), a global pharmaceutical Company, today announced its intention to appoint M/s. Deloitte Haskins & Sells LLP ("Deloitte") as its Statutory Auditors for a period of five consecutive years effective from Financial Year (FY) 2026-27 ending March 31, 2027. This proposed appointment is subject to the fulfillment of all applicable regulatory requirements, including auditor independence requirements for Dr. Reddy's and its subsidiaries, in accordance with laws and regulations in India and other jurisdictions, as applicable.

The Shareholders of the Company at 37<sup>th</sup> Annual General Meeting ("AGM") of the Company held on July 28, 2021, had approved the appointment of current Statutory Auditors, M/s. S.R. Batliboi & Associates LLP for a period of five consecutive years from the conclusion of the 37<sup>th</sup> AGM until the conclusion of the 42<sup>nd</sup> AGM. As mandated by the Companies Act, 2013, the Company is required to appoint new Statutory Auditors commencing from the conclusion of 42<sup>nd</sup> AGM of the Company to be held in 2026.

The Audit Committee after evaluating the credentials and independence of the proposed audit firm, has noted its preliminary intent to recommend Deloitte as the new Statutory Auditors. The Board of Directors at its meeting held today, i.e., July 23, 2025, have approved the announcement of Dr. Reddy's intention as aforesaid. The proposed appointment will be recommended to the shareholders of the Company for approval at the AGM to be held in 2026.

**About Dr. Reddy's**: Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of 'Good Health Can't Wait', we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include - USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: <u>www.drreddys.com.</u>

Dr. Reddy's Laboratories Limited; Reg. Office: 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India <br>

CIN: L85195TG1984PLC004507; Web: <u>www.drreddys.com;</u> Tel: + 91 40 4900 2900; Fax: + 91 40 4900 2999; Email: <u>mail@drreddys.com</u>

<br>